Tauriga Sciences Inc. Appoints Dr. Lawrence A. May as

LOS ANGELES, CA--(Marketwired - Apr 25, 2013) - Tauriga Sciences, Inc. ( OTCQB : TAUG ) or ("The Company") has today announced the appointment of Dr. Lawrence A. May ("Dr. May") as the second member of the Company's recently established medical advisory board. As the Company continues to evaluate potentially lucrative opportunities in the life sciences space, the advice of highly qualified and experienced individuals is of great importance. Dr. May brings 35 years of clinical experience as a prestigious physician of internal medicine and joins the Company's Chief Operating Officer, Dr. Stella M. Sung ("Dr. Sung"), on the Medical Advisory Board. The Company is working diligently to attract additional members to its Medical Advisory Board with the ultimate goal of securing five to seven outstanding members with the optimal balance of scientific and clinical expertise and relevant sector experience in medical devices, biopharmaceuticals, diagnostics and consumer health care. 

TAUG CEO Seth M. Shaw commented, "The Company is fortunate to have attracted an experienced and esteemed physician such as Dr. Lawrence May to its recently formed Medical Advisory Board. As the Company continues the process of evaluating potentially lucrative business opportunities, Dr. May's knowledge and network will prove highly valuable to the Tauriga's management team. The Company continues to prioritize the assembly of its Medical Advisory Board with individuals who have built impressive resumes and successful careers."

Newly appointed Medical Advisory Board member Dr. Lawrence May stated, "I am very excited for the opportunity to make meaningful contributions to the Company as we build a strong portfolio to increase shareholder value. From my many years of clinical practice, I have firsthand knowledge of emerging technologies that address the most important unmet medical needs." 

Please see below Bio for Lawrence A May MD FACP, age 64:

Lawrence May MD is a board certified internist with broad experience in clinical medicine, academics, media and business. Following residency he joined the faculty of the UCLA medical school where he directed the health services research center at the Wadsworth, VA hospital and served as a founder and co director of the center for health enhancement education and research {CHEER} at UCLA. He continued on the clinical faculty after entering private practice, Dr. May has written many books and articles including a widely used textbook entitled Primary Care Medicine. Dr. May became an important formulator of nutritional products and served as executive vice president for medical and scientific affairs for Herbalife international. He has appeared in the media, lectured internationally, and consulted to industry and medical institutions, as well as serving on their boards. He was a founder of physicians therapeutics and helped develop the parent Targeted Medical Pharma. He is an advisor to Stock News Now SNN, writes for microcap review and evaluates biopharmaceutical companies as an investor.

Dr. May received his undergraduate degree magna cum laude in economics from Harvard University ('70) where he was elected to phi beta kappa. His medical degree was also earned at Harvard Medical School ('74) and residency in internal medicine was served at Massachusetts General Hospital

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. ("the Company") is a life science holding company that focuses on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare. The mission of the Company is to acquire and build a diversified portfolio of medical technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at URL address ( www.taurigasciences.com ).

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission.